Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ACP1 | P24666 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.48 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10084083 | 0.81 | HDAC1 (0.45) | TRPV1RAB9AHSD17B10KDM4ENPC1 | |
| SCHEMBL10084086 | 0.81 | HDAC1 (0.45) | TRPV1RAB9AHSD17B10KDM4ENPC1 | |
| SCHEMBL14036078 | 0.80 | HDAC1 (0.49) | TRPV1RAB9AHSD17B10KDM4ENPC1 | |
| SCHEMBL29221826 | 0.80 | ACP1 (0.57) | RAB9AHSD17B10KDM4ENPC1SMN1; SMN2 | |
| SCHEMBL30858813 | 0.80 | ACP1 (0.57) | RAB9AHSD17B10KDM4ENPC1SMN1; SMN2 | |
| SCHEMBL29221824 | 0.80 | ACP1 (0.57) | RAB9AHSD17B10KDM4ENPC1SMN1; SMN2 | |
| SCHEMBL1245421 | 0.79 | RAB9A (0.56) | TRPV1RAB9AHSD17B10KDM4ENPC1 | |
| SCHEMBL1245420 | 0.79 | RAB9A (0.56) | TRPV1RAB9AHSD17B10KDM4ENPC1 | |
| SCHEMBL4951758 | 0.79 | RAB9A (0.56) | TRPV1RAB9AHSD17B10KDM4ENPC1 | |
| SCHEMBL2748084 | 0.79 | ACP1 (0.51) | TRPV1RAB9AHSD17B10KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268865-B2 | Quaternary alkyl ammonium bacterial efflux pump inhibitors and therapeutic uses thereof | REMPEX PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20120165276-A1 | QUATERNARY ALKYL AMMONIUM BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | MPEX PHARMACEUTICALS, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165276-A1 | QUATERNARY ALKYL AMMONIUM BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | MPEX PHARMACEUTICALS, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| WO-2008141012-A2 | QUATERNARY ALKYL AMMONIUM BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | MPEX PHARMACEUTICALS, INC. (US) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165276-A1 | QUATERNARY ALKYL AMMONIUM BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | ABCB11, ABCC1, SLC47A1 | TRPV1 1840/4885RAB9A 748/4885HSD17B10 1787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.